ASIC-E4: Interplay of Beta-Amyloid, Synaptic Density and Neuroinflammation in Cognitively Normal Volunteers With Three Levels of Genetic Risk for Late-Onset Alzheimer's Disease - Study Protocol and Baseline Characteristics.
APOE
Alzheimer's disease
SV2A ligand
TSPO (18 kDa translocator protein)
beta-amyloid
biomarker
neuroinflammation
preclinical
Journal
Frontiers in neurology
ISSN: 1664-2295
Titre abrégé: Front Neurol
Pays: Switzerland
ID NLM: 101546899
Informations de publication
Date de publication:
2022
2022
Historique:
received:
30
11
2021
accepted:
06
01
2022
entrez:
28
2
2022
pubmed:
1
3
2022
medline:
1
3
2022
Statut:
epublish
Résumé
Detailed characterization of early pathophysiological changes in preclinical Alzheimer's disease (AD) is necessary to enable development of correctly targeted and timed disease-modifying treatments. ASIC-E4 study ("Beta-Amyloid, Synaptic loss, Inflammation and Cognition in healthy Here, our objective is to describe the study design, used protocols and baseline demographics of the ASIC-E4 study. ASIC-E4 is a prospective observational multimodal imaging study performed in Turku PET Centre in collaboration with University of Gothenburg. Cognitively normal 60-75-year-old-individuals with known Results of the ASIC-E4 project will bridge the gap related to limited knowledge of the synaptic and inflammatory changes and their association with each other and Aβ in "at-risk" individuals. Thorough
Sections du résumé
BACKGROUND
BACKGROUND
Detailed characterization of early pathophysiological changes in preclinical Alzheimer's disease (AD) is necessary to enable development of correctly targeted and timed disease-modifying treatments. ASIC-E4 study ("Beta-Amyloid, Synaptic loss, Inflammation and Cognition in healthy
OBJECTIVE
OBJECTIVE
Here, our objective is to describe the study design, used protocols and baseline demographics of the ASIC-E4 study.
METHODS/DESIGN
METHODS
ASIC-E4 is a prospective observational multimodal imaging study performed in Turku PET Centre in collaboration with University of Gothenburg. Cognitively normal 60-75-year-old-individuals with known
DISCUSSION
CONCLUSIONS
Results of the ASIC-E4 project will bridge the gap related to limited knowledge of the synaptic and inflammatory changes and their association with each other and Aβ in "at-risk" individuals. Thorough
Identifiants
pubmed: 35222254
doi: 10.3389/fneur.2022.826423
pmc: PMC8863967
doi:
Types de publication
Journal Article
Langues
eng
Pagination
826423Subventions
Organisme : European Research Council
ID : 681712
Pays : International
Informations de copyright
Copyright © 2022 Snellman, Ekblad, Koivumäki, Lindgrén, Tuisku, Perälä, Kallio, Lehtonen, Saunavaara, Saunavaara, Oikonen, Aarnio, Löyttyniemi, Parkkola, Karrasch, Zetterberg, Blennow and Rinne.
Déclaration de conflit d'intérêts
HZ has served at scientific advisory boards and/or as a consultant for Abbvie, Alector, Annexon, Artery Therapeutics, AZTherapies, CogRx, Denali, Eisai, Nervgen, Pinteon Therapeutics, Red Abbey Labs, Passage Bio, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave, has given lectures in symposia sponsored by Cellectricon, Fujirebio, Alzecure and Biogen, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program. KB has served as a consultant, at advisory boards, or at data monitoring committees for Abcam, Axon, Biogen, JOMDD/Shimadzu. Julius Clinical, Lilly, MagQu, Novartis, Pharmatrophix, Prothena, Roche Diagnostics, and Siemens Healthineers, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Neurobiol Aging. 2018 Jan;61:207-214
pubmed: 29111487
Neurobiol Aging. 2010 Aug;31(8):1275-83
pubmed: 20472326
Transl Psychiatry. 2021 Jan 11;11(1):27
pubmed: 33431793
J Cereb Blood Flow Metab. 2018 Nov;38(11):2041-2052
pubmed: 28792356
Neurology. 2005 Jul 12;65(1):102-6
pubmed: 16009893
Alzheimers Dement (N Y). 2021 May 25;7(1):e12179
pubmed: 34095440
Neuron. 2019 Mar 6;101(5):820-838
pubmed: 30844401
Nat Med. 2021 Sep;27(9):1592-1599
pubmed: 34446931
Nat Commun. 2021 Jun 7;12(1):3400
pubmed: 34099648
Mol Psychiatry. 2011 Sep;16(9):903-7
pubmed: 21556001
J Cereb Blood Flow Metab. 2021 Sep;41(9):2395-2409
pubmed: 33757318
Mol Psychiatry. 2021 Feb;26(2):429-442
pubmed: 33106600
J Intern Med. 2021 Sep;290(3):583-601
pubmed: 34021943
Acta Neuropathol. 2021 May;141(5):709-724
pubmed: 33585983
J Alzheimers Dis. 2010;22(4):1089-97
pubmed: 20930314
Alzheimers Dement. 2018 Apr;14(4):535-562
pubmed: 29653606
Alzheimers Dement. 2020 Mar 10;:
pubmed: 32157811
Brain. 2016 Apr;139(Pt 4):1252-64
pubmed: 26984188
Alzheimers Res Ther. 2021 Mar 27;13(1):68
pubmed: 33773595
Nat Rev Drug Discov. 2010 Dec;9(12):971-88
pubmed: 21119734
JAMA. 2020 Aug 25;324(8):772-781
pubmed: 32722745
Alzheimers Res Ther. 2017 Sep 12;9(1):71
pubmed: 28899416
Front Neuroinform. 2020 Feb 04;14:3
pubmed: 32116627
Proc Natl Acad Sci U S A. 2009 Apr 21;106(16):6820-5
pubmed: 19346482
Science. 1993 Aug 13;261(5123):921-3
pubmed: 8346443
Nat Rev Neurol. 2013 Feb;9(2):106-18
pubmed: 23296339
JAMA Neurol. 2021 Dec 1;78(12):1471-1483
pubmed: 34661615
Nat Med. 2020 Mar;26(3):387-397
pubmed: 32123386
Nat Neurosci. 2020 Oct;23(10):1183-1193
pubmed: 32778792
Neuron. 2016 Mar 2;89(5):971-982
pubmed: 26938442
Nat Rev Neurol. 2016 Jan;12(1):56-61
pubmed: 26416539
Ann Neurol. 2011 Jan;69(1):181-92
pubmed: 21280088
Eur J Nucl Med Mol Imaging. 2009 Oct;36(10):1651-60
pubmed: 19495749
Neurol Neuroimmunol Neuroinflamm. 2018 Mar 06;5(3):e443
pubmed: 29520366
Sci Transl Med. 2016 Jul 20;8(348):348ra96
pubmed: 27440727
Nature. 2018 Feb 8;554(7691):249-254
pubmed: 29420472
J Alzheimers Dis. 2019;67(2):481-488
pubmed: 30594925
Neurobiol Aging. 2017 Sep;57:84-94
pubmed: 28605642
Lancet. 2016 Jul 30;388(10043):505-17
pubmed: 26921134
Neurology. 2021 Mar 23;96(12):e1608-e1619
pubmed: 33514647
Brain. 2017 Mar 1;140(3):792-803
pubmed: 28122877
Lancet Neurol. 2020 May;19(5):422-433
pubmed: 32333900
Front Aging Neurosci. 2019 Feb 11;11:14
pubmed: 30804776
Eur J Nucl Med Mol Imaging. 2021 Jul;48(7):2140-2156
pubmed: 33677733
Alzheimers Dement. 2020 Jul;16(7):974-982
pubmed: 32400950
Neurology. 2004 Mar 23;62(6):925-31
pubmed: 15037694
Alzheimers Dement. 2011 May;7(3):280-92
pubmed: 21514248
Alzheimers Res Ther. 2020 May 27;12(1):66
pubmed: 32460855
J Cereb Blood Flow Metab. 2012 Aug;32(8):1600-8
pubmed: 22588187
Ann Neurol. 2004 Mar;55(3):306-19
pubmed: 14991808